Roth Capital Remains Positive on Actinium Pharma (ATNM) as Iomab-B Gains Orphan Designation in Europe
- Asia stocks rise, yen plumbs 34-year low as BOJ stands pat on rates
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock soars 12% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B
October 18, 2016 7:00 AM EDT- Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained
-Â Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016
- Iomab-B now has orphan designation in the US and EU
NEW YORK, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the... More